Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKT5097 in Advanced/Metastatic Solid Tumors
NCT07029399Phase 1Recruiting
- Sponsor
- NiKang Therapeutics
- Start
- Mar 2025
- Primary completion
- Jul 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of NKT5097 in solid tumor and breast cancer (5 arms), sponsored by NiKang Therapeutics. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Mar 2025; status: recruiting.
02
Drugs
NKT5097
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT07029399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029399.